EyePoint Pharmaceuticals files $200M ATM equity offering with Cantor Fitzgerald

EyePoint, Inc.

Registered at-the-market offering of up to $200 million of common stock under a prospectus supplement filed November 6, 2025.
Sales agreement with Cantor Fitzgerald & Co. dated August 5, 2020 governs the offering.
Proceeds expected for general corporate purposes; legal opinion from Hogan Lovells filed as exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.